## Genencor R&D Laboratory, Netherlands Class D7 USD INC



#### December 2022

## **Investment Objective**

The Share Class invests in a single Research Laboratory leased to Genencor, a subsidiary of International Flavours & Fragrances (IFF), located in the Leiden University Bio-Science Park, The Netherland. The investment objective is to generate a regular income and grow capital over time by benefiting from progressive rental escalations. The investment makes use of limited recourse leverage to enhance returns and is hedged in USD. The current target dividend per share is \$7 per annum (paid monthly).

#### **Performance Overview**



## **Cumulative Net Performance (%)**

	Total Return	Distributions
2021 (*)	8.12	7.41
2022 YTD	-6.80	6.98

Source: Rasmala's Internal Performance Measurement Team (%)

Performance is net of fees and expenses based on the European Real Estate Income Fund D7 USD Income share class as of 31st December 2022

\*Launch date of performance measurement period is 3<sup>rd</sup> January 2021
Historical performance is not and should not be construed as being indicative for the future or likely performance.

## **Portfolio Manager Commentary**

The asset performed as expected despite the economic stresses across the property sector. Rents were collected on time and with cost of finance fixed until 2025 ensure a stable income stream for investors, hence, holders of shares received their monthly distributions of \$0.58 per share, equivalent to an annualized yield of 7% of issue price. 1,2

The decline in value of the property on 31st December over the year was caused by the higher interest rates, to tackle high inflation, which are impacting the overall European property market. In particular, logistics sector recorded higher than market declines due to the low yields which were recorded at the beginning of the year. Given the strong growth of rents in the sector, we expect that this decline in value will be temporary and that it should be recovered over the next 3-5 years. 1,2

The currency hedging strategy has worked well since inception and has delivered a substantial cash payout in December. Going forward, given the current low level of the Euro, we have decided to partially reduce the currency cover to avoid that future appreciation of the Euro versus the USD drains liquidity and triggers a margin call. This is expected to increase the sensitivity of the share price to movements of the EUR but is expected contribute positively to the total return over time.1

Looking forward, JLL expects activity in the sector to remain steady in the next 12 months, although economic uncertainty, continued investment and occupier supply constraints, and a reduction in VC investment will impact activity. The market will proceed to produce healthcare advancements, but caution will remain a constant.

## Sources

- Rasmala Real Estate Team
- <sup>2</sup> CBRE Valuation Q4 22
- <sup>3</sup> JLL life science cluster report 2023



Share Class Information		
Issuer	Rasmala European Real Estate Income Fund	
Share Class	Class D7 USD INC	
Currency	USD	
Asset Type	Office and Laboratory	
Location	Leiden, Netherlands	
Tenant	Genencor International B.V (DuPont	
Dividend Frequency	Monthly	
ISIN Number	KYG738782930	
NAV/Share	\$87.60	
Monthly Dividend	\$0.58	
Inception Date	03/01/2021	
Investment Manager	Rasmala Investment Bank Limited	
Administrator	Apex Fund Services Ltd.	
Auditor	PricewaterhouseCoopers	
Legal Advisors	Maples & Calder LLP	
Sharia Advisor	Dar Al Sharia Limited	

Asset Information <sup>1,2</sup>			
Asset Class	Office and Laboratory		
Property Valuation	€33,569,274		
Last Valuation Report	31 Dec 2022		
LTV	56%		
Loan	€18,900,000		
Rental Reviews	Annual, CPI cap Rent Review March 2023		
Rental cap	4.96%		
Rent expiry date	17 Mar 2038		
Annual Rent	€1,727,692		
Market Rent	€1,710,665		
Under/Over Rented	+1%		









# Genencor R&D Laboratory, Netherlands Class D7 USD INC



## Distribution policy and capital depletion

The share class aims to make regular distributions at a pre-announced rate reviewed on a quarterly basis by the Directors of the Fund. Distribution rates are set on the basis of the average anticipated total return of the share class, are funded by available cash and can exceed the income of the underlying investment. In the event that the rate of distributions falls short of the total return achieved during a given period, the share price will decline by an amount corresponding to the shortfall leading to capital depletion.

Disclaimer: Rasmala Investment Bank Limited ("RIBL") is regulated by the Dubai Financial Services Authority ("DFSA"). RIBL products and services are only made available to customers who RIBL is satisfied meet the regulatory criteria to be "Professional Clients", as defined by the DFSA. RIBL does not deal with Retail clients.

This document is provided for information purposes only. It does not constitute a solicitation, recommendation or offer to buy or sell any specific investment product or subscribe to any specific investment management or advisory service. Reliance upon information in this material is at the sole discretion of the reader. This information, including any expression of opinion, has been obtained from or is based upon sources believed to be reliable at the time of writing, and is believed to be fair and not misleading. Any opinion or estimate contained in this material is subject to change without reference or notification to you. Calculations are based on the most recent data available from underlying sources. Neither RIBL nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, timeliness or completeness of the information, nor do they accept any responsibility arising in any way (including by negligence) for errors in or omissions from

This document is not for distribution to the general public but for intended recipients only and may not be published, circulated, reproduced or distributed in whole or part to any other person without the written consent of RIBL. This document is directed only to persons authorized to invest in the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the Fund / investment product as applicable and residing in jurisdictions where the fund / investment product is applicable and residing in jurisdictions where the fund / investment product is applicable and residing in jurisdictions where the fund / investment product is applicable and residing in jurisdictions where the fund / investment is applicable and residing in jurisdictions where the fund / investment is applicable and residing in jurisdictions where the fund / investment is applicable and residing in jurisdictions where the fund / investment is applicable and residing in jurisdictions where the fund / investment /

Investment involves risk. Prospective investors in the Fund product must obtain and carefully read the Fund's most recent Term Sheet, Offering Memorandum/Prospectus, Supplement (if any), and financial statements, as well as seek separate, independent legal, tax, regulatory and financial advice prior to making an investment in the Fund to assess the suitability (considering specific investment objective, financial situation or particular needs), lawfulness and risks involved. The Fund / investment product is intended for sophisticated investors only who understand the risks involved in investing in the Fund / investment product and can withstand any potential loss therefrom. Changes in exchange rates may have an adverse effect on the value, price or income of the products or underlying overseas investments. Historical performance is not and should not be construed as being indicative for the future or likely performance and no representation or warranty is made regarding future performance. The information contained herein does not have any regard to the specific investment objectives, financial situation or the particular needs of any person.







